Eli Lilly Says It Warned Doctors Of Cymbalta 'Brain Zaps'

Law360, Los Angeles (April 29, 2013, 10:24 PM EDT) -- Eli Lilly & Co. urged a California federal judge on Monday to toss a class action alleging inadequate labeling of its antidepressant Cymbalta, saying it sufficiently disclosed to doctors the risk that discontinuing use of the drug would cause “brain zaps” and other side effects.

Lilly's attorney Phyllis Jones of Covington & Burling LLP said the disclosures were sufficient for the claims of four consumers, including one physician, to be dismissed under the learned intermediary doctrine, which shields a drug manufacturer from liability when it provides...
To view the full article, register now.

Related

Sections

Case Information

Case Title

Jennifer L Saavedra v. Eli Lilly and Company


Case Number

2:12-cv-09366

Court

California Central

Nature of Suit

Contract: Other

Judge

Stephen V. Wilson

Date Filed

October 31, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.